| Literature DB >> 20060006 |
Rami Abu Fanne1, Taher Nassar, Sergei Yarovoi, Anwar Rayan, Itschak Lamensdorf, Michael Karakoveski, Polianski Vadim, Mahmud Jammal, Douglas B Cines, Abd Al-Roof Higazi.
Abstract
Tissue type plasminogen activator (tPA) can induce neuronal apoptosis, disrupt the blood-brain barrier (BBB), and promote dilation of the cerebral vasculature. The timing, sequence and contributions of these and other deleterious effects of tPA and their contribution to post-ischemic brain damage after stroke, have not been fully elucidated. To dissociate the effects of tPA on BBB permeability, cerebral vasodilation and protease-dependent pathways, we developed several tPA mutants and PAI-1 derived peptides constructed by computerized homology modeling of tPA. Our data show that intravenous administration of human tPA to rats increases BBB permeability through a non-catalytic process that is associated with reversible neurotoxicity, brain damage, mortality and contributes significantly to its brief therapeutic window. Furthermore, our data show that inhibiting the effect of tPA on BBB function without affecting its catalytic activity, improves outcome and significantly extends its therapeutic window in mechanical as well as in thromboembolic models of stroke. (c) 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20060006 PMCID: PMC4423729 DOI: 10.1016/j.neuropharm.2009.12.017
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250